Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant...
-
Upload
oliver-grant -
Category
Documents
-
view
225 -
download
4
Transcript of Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant...
![Page 1: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/1.jpg)
Dealing with the haemato-Dealing with the haemato-oncology patient in intensive careoncology patient in intensive care
Dr Tim Wigmore FRCA, FJFICMDr Tim Wigmore FRCA, FJFICM
Consultant Intensivist, Royal Marsden Consultant Intensivist, Royal Marsden HospitalHospital
![Page 2: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/2.jpg)
ICM at the MarsdenICM at the Marsden
11 Level 3 beds in Chelsea11 Level 3 beds in Chelsea 2 HDU beds in Sutton2 HDU beds in Sutton 900 admissions per year900 admissions per year
– 70% elective/emergency surgical70% elective/emergency surgical– 30% mix of various medical 30% mix of various medical
oncologyoncology– 5-6% Haemato-oncology5-6% Haemato-oncology
![Page 3: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/3.jpg)
Outcomes for Haemato-oncology Outcomes for Haemato-oncology patientspatients
Prognostic indicatorsPrognostic indicators General Admission strategyGeneral Admission strategy Bone Marrow Transplant patientsBone Marrow Transplant patients Prognostic indicatorsPrognostic indicators Common problems with BMTsCommon problems with BMTs Admission strategy for BMTsAdmission strategy for BMTs
![Page 4: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/4.jpg)
Improving outcomesImproving outcomes
General trends for the haemato-General trends for the haemato-oncology patientoncology patient
ICU MortalityICU Mortality
![Page 5: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/5.jpg)
Relative survival from NHLRelative survival from NHL
![Page 6: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/6.jpg)
Relative survival from multiple myelomaRelative survival from multiple myeloma
Source :CR-UK
![Page 7: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/7.jpg)
Relative survival from leukamiaRelative survival from leukamia
Source :CR-UK
![Page 8: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/8.jpg)
ICU Mortality – Bone Marrow ICU Mortality – Bone Marrow TransplantsTransplants
Azoulay 2009
![Page 9: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/9.jpg)
RMH ICU Haemato-oncology data RMH ICU Haemato-oncology data 2005-20092005-2009
1 in 4 Haem-Onc Patients need ICU1 in 4 Haem-Onc Patients need ICU n=199n=199 43% (n=87) post bone marrow 43% (n=87) post bone marrow
transplanttransplant Apache 24.7 +/-7.6Apache 24.7 +/-7.6 Mortality 38.2% (ICU) Mortality 38.2% (ICU)
51.4% (Hospital)51.4% (Hospital)
![Page 10: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/10.jpg)
ICNARC data for Haem-Onc patients ICNARC data for Haem-Onc patients 1995-20071995-2007
![Page 11: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/11.jpg)
Comparative Haem-Onc Comparative Haem-Onc MortalityMortality
![Page 12: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/12.jpg)
What has changedWhat has changed
New drugsNew drugs– GCSFGCSF– New antibiotics and antifungalsNew antibiotics and antifungals
New techniquesNew techniques– Less myeloablative techniquesLess myeloablative techniques– More autologous transplantsMore autologous transplants
Changes in ICU careChanges in ICU care– Early ICU admissionEarly ICU admission– GDTGDT– Less therapeutic nihilismLess therapeutic nihilism
![Page 13: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/13.jpg)
Debunking the mythsDebunking the myths
Disease statusDisease status NeutropeniaNeutropenia SepsisSepsis Recent chemotherapyRecent chemotherapy Mechanical VentilationMechanical Ventilation
![Page 14: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/14.jpg)
Disease prognosis does not affect ICU survivalDisease prognosis does not affect ICU survival
Massion et al, CCM 2002
![Page 15: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/15.jpg)
Neutropenia does not affect ICU survivalNeutropenia does not affect ICU survival
Darmon et al , ICM 2002
![Page 16: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/16.jpg)
Sepsis has a similar ICU outcome in Cancer and non-Sepsis has a similar ICU outcome in Cancer and non-Cancer patientsCancer patients
Pene et al, CCM 2008
![Page 17: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/17.jpg)
Use of chemotherapy prior to admission does not affect ICU Use of chemotherapy prior to admission does not affect ICU
survivalsurvival
Vandijck et al, ICM 2008
![Page 18: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/18.jpg)
Ventilation Ventilation in the first 24hrsin the first 24hrs does not affect survival in does not affect survival in ICUICU
• ICNARC review of haemato-oncology ICU admissions
IMV within 24 hours of admission not associated with increased mortality after adjustment for other prognostic factors
70.2% of intubated patients died in hospital
45.3% of non-intubated died in hospital
![Page 19: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/19.jpg)
RMH ICU results for patients ventilated in the RMH ICU results for patients ventilated in the first 24 hoursfirst 24 hours
N=81N=81 ICU mortality 58.8%ICU mortality 58.8% Hospital mortality 64.7%Hospital mortality 64.7%
6 month mortality 72.5%.6 month mortality 72.5%.
![Page 20: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/20.jpg)
What What does does predict predict outcomes ?outcomes ?
– Organ failure Organ failure √√– Progression of organ failure Progression of organ failure √√
![Page 21: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/21.jpg)
Organ failureOrgan failure– High initial organ failure scoreHigh initial organ failure score– Progress of organ dysfunction Progress of organ dysfunction – Development of OF post admissionDevelopment of OF post admission
![Page 22: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/22.jpg)
Initial SOFA scores predict Initial SOFA scores predict survivalsurvival
Cornet et al, Eur J Haematol 2005
![Page 23: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/23.jpg)
Progress of OF predicts survivalProgress of OF predicts survival
Lecuyer et al, CCM 2007
![Page 24: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/24.jpg)
Development of Development of latelate Organ Failures predicts death Organ Failures predicts death
Time refers to time from admission to development of organ failure
Black dot = Non survivor
Open triangle = survivor
![Page 25: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/25.jpg)
OF progression predicts death but not OF progression predicts death but not foolproof !foolproof !
Lamia et al ICM Oct 2006
Above the line = Deteriorating organ statusBlack dot = SurvivorClear dot = Non survivor
![Page 26: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/26.jpg)
Scoring systemsScoring systems
Most scoring systems fare badlyMost scoring systems fare badly Tendency to underestimate Tendency to underestimate
mortalitymortality Accurate at extremesAccurate at extremes ICMM designed specifically for ICMM designed specifically for
cancer patientscancer patients
![Page 27: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/27.jpg)
So…who should I admit to ICU ?So…who should I admit to ICU ?
Survival has improved for critically ill Survival has improved for critically ill cancer patientscancer patients
Classic predictors of mortality have Classic predictors of mortality have lost much of their valuelost much of their value
The characteristics of the malignancy The characteristics of the malignancy are not associated with ICU mortalityare not associated with ICU mortality
Scoring systems do not perform wellScoring systems do not perform well Mortality depends on organ failures at Mortality depends on organ failures at
presentation and at 3 dayspresentation and at 3 days
![Page 28: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/28.jpg)
So…who should I admit to ICU ?So…who should I admit to ICU ?
Request for admission to ICU
Bedridden patients
Very poor disease prognosis
Patient refuses
No ICU admission
All other patients
4 day trial admission with full treatment with re-assessment on day 5
Prev untreated
Tumour lysis
Patients in remission
Full ICU management
![Page 29: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/29.jpg)
Bone marrow transplantationBone marrow transplantation
50-60,000/yr – Most autologous50-60,000/yr – Most autologous Most commonMost common
– Multiple myelomaMultiple myeloma– NHLNHL– AMLAML– HodgkinsHodgkins
Approx 15% end up in ICUApprox 15% end up in ICU
![Page 30: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/30.jpg)
Bone marrow TransplantationBone marrow Transplantation
PreconditioningPreconditioning– ChemotherapyChemotherapy– RadiotherapyRadiotherapy– Ablative vs non-ablativeAblative vs non-ablative
Stem cell sourceStem cell source– AutologousAutologous– Allogeneic Allogeneic
CordCord Matched relatedMatched related Matched unrelatedMatched unrelated
![Page 31: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/31.jpg)
Reasons for admission to ICUReasons for admission to ICU
![Page 32: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/32.jpg)
RMH ICU BMT dataRMH ICU BMT data
N=87N=87 ICU mortality 36.8% ICU mortality 36.8% Hospital mortality 49.4%Hospital mortality 49.4% 6-month mortality 63.2%6-month mortality 63.2%
![Page 33: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/33.jpg)
BMT prognosis in ICUBMT prognosis in ICU
Predictors of good outcomePredictors of good outcome– AutograftAutograft
– Younger ageYounger age
– Resp failureResp failure Pulmonary OedemaPulmonary Oedema Bacterial PneumoniaBacterial Pneumonia
– Ventilation for less than 7 Ventilation for less than 7 daysdays
Predictors of poor outcomePredictors of poor outcome– AllograftAllograft
GVHDGVHD Increasing HLA mismatchIncreasing HLA mismatch
– Increasing AgeIncreasing Age– Recurrent malignancyRecurrent malignancy– Resp failureResp failure
DAHDAH IPSIPS BOOPBOOP CMV, RSVCMV, RSV AspergillosisAspergillosis
– Ventilation for more than 7 Ventilation for more than 7 daysdays
![Page 34: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/34.jpg)
Huynh et al. Outcome and Prognostic Indicators of Patients with Hematopoietic Stem Cell Transplants Admitted to the Intensive Care Unit
![Page 35: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/35.jpg)
Invasive Ventilation and mortality for BMT Invasive Ventilation and mortality for BMT recipientsrecipients
Afessa, and Azoulay, Crit Care Clinics Jan 2010
![Page 36: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/36.jpg)
So…which BMT do I admit to ICU ?So…which BMT do I admit to ICU ?
ICU admissionICU admission– Pre-engraftmentPre-engraftment– No recurrenceNo recurrence
ICU trialICU trial– Unknown disease statusUnknown disease status– Recurrence with available treatment optionsRecurrence with available treatment options
RefusalRefusal– Disease recurrence with no treatment optionsDisease recurrence with no treatment options– BedriddenBedridden– Severe GVHDSevere GVHD
![Page 37: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/37.jpg)
InfectionInfection
Pre-engraftment (0-30 days)Pre-engraftment (0-30 days)– Neutropenia and breaks in mucocutaneous barriersNeutropenia and breaks in mucocutaneous barriers
BacteriaBacteria CandidaCandida AspergillusAspergillus
Early post engraftmentEarly post engraftment– Impaired cell mediated immunityImpaired cell mediated immunity
CMVCMV PCPPCP AspergillusAspergillus
Late post engraftmentLate post engraftment– Impaired cell mediated and humoral immunity (partic in allogeneic)Impaired cell mediated and humoral immunity (partic in allogeneic)
VirusesViruses HaemophilusHaemophilus StrepStrep TBTB
![Page 38: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/38.jpg)
CXR cluesCXR clues
LobarLobar DiffuseDiffuse Acute intersititialAcute intersititial CavitatingCavitating
Upper lobesUpper lobes
Bacterial Bacterial OpportunisticOpportunistic ViralViral TB, Klebsiella, TB, Klebsiella,
Staph, NocardiaStaph, Nocardia TB, Klebsiella, TB, Klebsiella,
Meliodosis, Meliodosis, Aspergillus, Aspergillus, Pneumocystis, CMVPneumocystis, CMV
![Page 39: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/39.jpg)
Investigation of Respiratory failureInvestigation of Respiratory failure
![Page 40: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/40.jpg)
Respiratory failure in the BMT Respiratory failure in the BMT patientpatient
30 60 90
Virus CMV, RSV, Adenovirus, VZV, EBV
Bacteria Gram +ve or -ve Intracellular, Encapsulated
Fungi Candida Aspergillus, PCP Emerging fungal infections
Non- infectious
Pulm Oedema
DAH
Engraftment synd IPS COP, BO, Pulm GVHD
Infectious
Days since BMT0
![Page 41: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/41.jpg)
NPPV in BMTNPPV in BMT
Possibly decreases mortality Possibly decreases mortality – Azoulay et al CCM 2001Azoulay et al CCM 2001– Afessa et al CCM 2003Afessa et al CCM 2003– Pene et al J Clin Oncol 06Pene et al J Clin Oncol 06
Small numbers in the trialsSmall numbers in the trials Requires early intervention and Requires early intervention and
acutely reversible causeacutely reversible cause Anecdotal experience at RMHAnecdotal experience at RMH
![Page 42: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/42.jpg)
Other potential Other potential problems problems GvHDGvHD Tumour LysisTumour Lysis Veno-occlusive disease (VOD)Veno-occlusive disease (VOD) Blood product supportBlood product support
![Page 43: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/43.jpg)
GvHDGvHD
Classic TriadClassic Triad Can affect lung alsoCan affect lung also Management via (more) Management via (more)
immunosuppressionimmunosuppression
![Page 44: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/44.jpg)
Veno-occlusive diseaseVeno-occlusive disease
Occurs in first 21 days post TxOccurs in first 21 days post Tx Due to Hepatic endothelial damage from pre-Due to Hepatic endothelial damage from pre-
conditioningconditioning Thrombosis leads to Thrombosis leads to
– Weight gainWeight gain– HepatomegalyHepatomegaly– HyperbilirubinaemiaHyperbilirubinaemia– AscitesAscites
Diagnosis with DopplerDiagnosis with Doppler Defibrotide has drastically reduced incidence and Defibrotide has drastically reduced incidence and
mortalitymortality
![Page 45: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/45.jpg)
Tumour LysisTumour Lysis
Typically following induction Typically following induction chemotherapy for leukaemia or chemotherapy for leukaemia or lymphomalymphoma
Predicted by an LDH>1500Predicted by an LDH>1500 Up to a third occur spontaneouslyUp to a third occur spontaneously
![Page 46: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/46.jpg)
Causes release of purines, Causes release of purines, potassium and phosphatepotassium and phosphate
ConsequentConsequent– Life threatening arrhythmiasLife threatening arrhythmias– ARF (uric acid and calcium ARF (uric acid and calcium
phosphate deposition)phosphate deposition)
![Page 47: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/47.jpg)
Purines from nucleic acids
Xanthine
Uric acid (Insoluble)
Allantoin (soluble)
Deposits in kidney leading to ARF Urate
Oxidase
Xanthine Oxidase
Rasburicase
Allopurinol
![Page 48: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/48.jpg)
ProphylaxisProphylaxis– HydrationHydration– Allopurinol or rapspuricaseAllopurinol or rapspuricase– Avoid urine alkalinization (xanthines more insoluble Avoid urine alkalinization (xanthines more insoluble
in alkaline urine)in alkaline urine) TreatmentTreatment
– SymptomaticSymptomatic– Avoid correcting hypocalcaemia unless ECG Avoid correcting hypocalcaemia unless ECG
changeschanges– RasburicaseRasburicase– Filtration Filtration
![Page 49: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/49.jpg)
Blood product supportBlood product support
All products must be irradiated All products must be irradiated – Risk of fatal GvHD from Tx T Risk of fatal GvHD from Tx T
lymphocyteslymphocytes All patients should have CMV –ve All patients should have CMV –ve
products (even if CMV +ve preTx)products (even if CMV +ve preTx)– If non available, leucodepleted red If non available, leucodepleted red
cells of platelets can be used in prev cells of platelets can be used in prev CMV +ve ptsCMV +ve pts
![Page 50: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/50.jpg)
In conclusionIn conclusion
Outcomes are improvingOutcomes are improving Therapeutic nihilism is self fulfillingTherapeutic nihilism is self fulfilling
BUT….BUT…. Heavy users of resourceHeavy users of resource Trials of admission require a clear Trials of admission require a clear
understanding and a close understanding and a close relationship with the relatives and relationship with the relatives and haematologists !haematologists !
![Page 51: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/51.jpg)
Early versus late admission to ICUEarly versus late admission to ICU
Larche et al ICM 2003
![Page 52: Dealing with the haemato-oncology patient in intensive care Dr Tim Wigmore FRCA, FJFICM Consultant Intensivist, Royal Marsden Hospital.](https://reader036.fdocuments.in/reader036/viewer/2022062321/56649e225503460f94b0e7a1/html5/thumbnails/52.jpg)
Bigger units get better Bigger units get better resultsresults Lecuyer et al, euro resp journal Lecuyer et al, euro resp journal
20082008